Israel Englander Bristol Myers Squibb CO Transaction History

Millennium Management LLC

$224 Billion
Q1 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Millennium Management LLC holds 591,200 shares of BMY stock, worth $24.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

591,200

Previous 282,500 109.27%

Holding current value

$24.3 Million

Previous $14.5 Million 121.18%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $119 Million - $135 Million	-2,474,633 Reduced 99.48%	12,960 $702,000
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $40 Million - $47.8 Million	825,614 Added 49.68%	2,487,593 $128 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $630,474 - $700,043	9,896 Added 0.6%	1,661,979 $106 Million
Q1 2023 May 15, 2023	BUY	$65.71 - $74.53 $98.3 Million - $112 Million	1,496,107 Added 959.19%	1,652,083 $115 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $8.56 Million - $10.1 Million	125,051 Added 404.37%	155,976 $11.2 Million

Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $40,929 - $24.2 Million	-314,845 Reduced 91.06%	30,925 $2.2 Million
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $97.4 Million - $107 Million	-1,341,776 Reduced 79.51%	345,770 $26.6 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $112 Million - $134 Million	-1,819,552 Reduced 51.88%	1,687,546 $123 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $127 Million - $148 Million	2,370,388 Added 208.53%	3,507,098 $219 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $65.4 Million - $76.6 Million	-1,104,596 Reduced 49.28%	1,136,710 $67.3 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $38.9 Million - $42.3 Million	-627,710 Reduced 21.88%	2,241,306 $150 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $3.55 Million - $3.99 Million	59,836 Added 2.13%	2,869,016 $181 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $89.1 Million - $101 Million	-1,543,208 Reduced 35.46%	2,809,180 $174 Million
Q3 2020 Nov 16, 2020	BUY	$57.43 - $63.64 $80.5 Million - $89.2 Million	1,401,543 Added 47.5%	4,352,388 $262 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $98.4 Million - $115 Million	1,795,182 Added 155.34%	2,950,845 $174 Million
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $40.5 Million - $58.9 Million	873,406 Added 309.44%	1,155,663 $64.4 Million
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $6.86 Million - $8.94 Million	-139,343 Reduced 33.05%	282,257 $18.1 Million
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $15.5 Million - $18.3 Million	-361,324 Reduced 46.15%	421,600 $21.4 Million
Q2 2019 Aug 15, 2019	BUY	$44.62 - $49.34 $26 Million - $28.8 Million	582,748 Added 291.12%	782,924 $35.5 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $228 Million - $253 Million	-5,120,459 Reduced 96.24%	200,176 $5.49 Million
Q1 2019 May 14, 2019	SELL	$45.12 - $53.8 $84.9 Million - $101 Million	-1,882,341 Reduced 26.13%	5,320,635 $254 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $238 Million - $309 Million	4,890,444 Added 211.48%	7,202,976 $374 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $96.9 Million - $109 Million	1,754,905 Added 314.71%	2,312,532 $144 Million
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $110 Million - $137 Million	-2,169,186 Reduced 79.55%	557,627 $30.9 Million
Q1 2018 May 15, 2018	BUY	$59.92 - $68.98 $39.9 Million - $45.9 Million	665,890 Added 32.31%	2,726,813 $172 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $1.08 Million - $1.18 Million	18,064 Added 0.88%	2,060,923 $126 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $113 Million - $130 Million	2,042,859	2,042,859 $130 Million

Others Institutions Holding BMY

# of Institutions

2,552

Shares Held

1.49B

Call Options Held

25.9M

Put Options Held

20M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $87.4B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account